NASDAQ:SGHT Sight Sciences Q3 2025 Earnings Report $3.22 -0.16 (-4.59%) As of 11:17 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Sight Sciences EPS ResultsActual EPSN/AConsensus EPS -$0.26Beat/MissN/AOne Year Ago EPSN/ASight Sciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASight Sciences Announcement DetailsQuarterQ3 2025Date11/6/2025TimeBefore Market OpensConference Call DateThursday, November 6, 2025Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Sight Sciences Earnings HeadlinesSight Sciences price target lowered to $4 from $4.50 at CitiOctober 7 at 3:19 PM | msn.comAnalysts Set Sight Sciences, Inc. (NASDAQ:SGHT) Target Price at $4.42October 5, 2025 | americanbankingnews.comTrump to get REVENGE on the banks??Rumors are swirling that Trump could target the banking system by upending the $5 trillion-a-day SWIFT network — and one $3 asset, with nine ETFs already in the works, may skyrocket if his plan moves forward.October 10 at 2:00 AM | The Oxford Club (Ad)Sight Sciences Amends Loan Agreement with HerculesSeptember 30, 2025 | tipranks.comSight Sciences announces publication of results on OMNI Surgical SystemSeptember 17, 2025 | msn.comSight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in ...September 17, 2025 | markets.businessinsider.comSee More Sight Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sight Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sight Sciences and other key companies, straight to your email. Email Address About Sight SciencesSight Sciences (NASDAQ:SGHT) is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy. Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model. Its clinical programs have explored both standalone and adjunctive uses of its platforms, seeking to expand indications in glaucoma management and ocular surface disease. The company continues to invest in iterative improvements and new treatment modalities built upon its core thermal and micro-invasive glaucoma surgery (MIGS) technologies. Headquartered in Menlo Park, California, Sight Sciences distributes its products across the United States and has established partnerships to serve markets in Canada, Europe and Australia. The company supports its customers with training programs, surgical support services and a dedicated clinical affairs team to gather real-world evidence and refine procedural protocols. Leadership at Sight Sciences includes President and Chief Executive Officer Gregg Prentice, who brings deep experience in medical device commercialization, and a management team with expertise in ophthalmology, regulatory affairs and commercial operations. The company’s board and executive ranks blend industry veterans with academic researchers, underscoring its commitment to advancing eye care through innovation.View Sight Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings Fastenal (10/13/2025)Wells Fargo & Company (10/14/2025)Citigroup (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)The Goldman Sachs Group (10/14/2025)BlackRock (10/14/2025)ASML (10/15/2025)Kinder Morgan (10/15/2025)Bank of America (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
